Login to Your Account

Clinic Roundup

Thursday, March 17, 2011
Repros Therapeutics Inc., of The Woodlands, Texas, dosed its first patients in a low-dose study of Proellex for uterine fibroids and endometriosis. Previous studies at a 50-mg dose were held when some subjects experienced severe liver toxicity. The new study will enroll five cohorts at doses from 1 mg to 12 mg per day, starting with the lowest cohort and not progressing to the next dose until an outside drug safety monitoring committee has reviewed the liver safety data from the previous.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription